
Immuneering
(NASDAQ) IMRX
Immuneering Financials at a Glance
Market Cap
$322.84M
Revenue (TTM)
$0.00
Net Income (TTM)
-$54.44M
EPS (TTM)
-$1.17
P/E Ratio
-4.28
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Price
$5.05
Volume
1,102,004.122
Open
$4.99
Price
$5.05
Volume
1,102,004.122
Open
$4.99
Previous Close
$5.05
Daily Range
$4.88 - $5.18
52-Week Range
$2.90 - $10.08
Estimated Earnings Date
Aug 12, 2026
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Price
$5.05
Volume
1,102,004.122
Open
$4.99
Previous Close
$5.05
Daily Range
$4.88 - $5.18
52-Week Range
$2.90 - $10.08
Estimated Earnings Date
Aug 12, 2026
IMRX News
IMRX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Immuneering
Industry
Biotechnology
Sector
Health CareEmployees
55
CEO
Benjamin J. Zeskind, PhD, MBA
Website
www.immuneering.comHeadquarters
Cambridge, MA 02142, US
IMRX Financials
Key Financial Metrics (TTM)
Gross Margin
0.00%
Operating Margin
0.00%
Net Income Margin
0.00%
Return on Equity
-0.11%
Return on Capital
-26.71%
Return on Assets
-0.03%
Earnings Yield
-23.36%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$322.84M
Shares Outstanding
64.70M
Volume
1.10M
Avg. Volume
1.47M
Financials (TTM)
Gross Profit
-$793.21K
Operating Income
-$59.23M
EBITDA
-$58.85M
Operating Cash Flow
-$49.70M
Capital Expenditure
-$213.21K
Free Cash Flow
-$49.91M
Cash & ST Invst.
$156.69M
Total Debt
$3.73B
Immuneering Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
-$180.48K
N/A
Gross Margin
0.00%
N/A
Market Cap
$322.84M
N/A
Market Cap/Employee
$5.98M
N/A
Employees
54
N/A
Net Income
-$13.46M
+10.5%
EBITDA
-$15.15M
+1.5%
Quarterly Fundamentals
Total Cash
$156.69M
+336.9%
Total Debt
$3.73B
+91265.7%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$3.32B
+88921.7%
Short Term Debt
$413.25M
+117126.4%
Return on Assets
-0.03%
N/A
Return on Invested Capital
-0.03%
N/A
Free Cash Flow
-$18.51M
-31.4%
Operating Cash Flow
-$18.43M
-30.9%

